tiprankstipranks

Daniel Junius Insider Profile

4 Followers
Daniel Junius, Director at ImmunoGen, holds 98.46K shares in GlycoMimetics (Ticker: GLYC), holds 3.04K shares in Idexx Laboratories (Ticker: IDXX), holds 184.99K shares in ImmunoGen (Ticker: IMGN).
tipranks
Daniel Junius

Daniel Junius
ImmunoGen (IMGN)
Director

Ranked #58,392 out of 99,335 Corporate Insiders

Profitable Transactions

43%
13 out of 30 Profitable Transactions

Average Return

-1.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$1M
97.51%
2.49%
A breakdown of Daniel Junius's holdings

Insider Roles

Idexx Laboratories
(IDXX)
Director
GlycoMimetics
(GLYC)
Director
Roles that Daniel Junius holds in companies

Most Profitable Insider Trade

Stock:
GlycoMimetics
(GLYC)
Rating:Informative Buy
Date:Dec 21, 2016 - Dec 21, 2017
Return:+168.10%
The most profitable trade made by Daniel Junius

Daniel Junius's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
IMGN
ImmunoGen
Feb 23, 2018
Informative Sell
140.56K
$5.78M
GlycoMimetics
Apr 02, 2024
Director
Uninformative Buy
15.63K
$32.49K
VTAE
Vitae Pharma
Idexx Laboratories
Feb 01, 2024
Director
Uninformative Buy
7.29K
$1.27M
List of latest transactions for each holding click on a transaction to see Daniel Junius's performance on stock

Daniel Junius insider profile FAQ

What is the percentage of profitable transactions made by Daniel Junius?
The percentage of profitable transactions made by Daniel Junius is 43%.
    What is the average return per transaction made by Daniel Junius?
    The average return per transaction made by Daniel Junius is -1.90%.
      What stocks does Daniel Junius hold?
      Daniel Junius holds: IMGN, GLYC, VTAE, IDXX stocks.
        What was Daniel Junius’s latest transaction?
        Daniel Junius latest transaction was an Uninformative Buy of $15.63K.
          What was Daniel Junius's most profitable transaction?
          Daniel Junius’s most profitable transaction was an Informative Buy of GLYC stock on December 21, 2016. The return on the trade was 168.10%.
            What is Daniel Junius's role in ImmunoGen?
            Daniel Junius's role in ImmunoGen is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.